Document is current
Any future updates will be listed below
-
Authors
Pridham, Kevin J. https://orcid.org/0000-0002-2636-9688
Shah, Farah
Hutchings, Kasen R. https://orcid.org/0000-0001-5959-4526
Sheng, Kevin L.
Guo, Sujuan
Liu, Min
Kanabur, Pratik
Lamouille, Samy
Lewis, Gabrielle
Morales, Marc
Jourdan, Jane
Grek, Christina L.
Ghatnekar, Gautam G.
Varghese, Robin
Kelly, Deborah F.
Gourdie, Robert G. https://orcid.org/0000-0001-6021-0796
Sheng, Zhi https://orcid.org/0000-0002-0029-8666
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA216768)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA245631)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (HL56728)
U.S. Department of Health & Human Services | National Institutes of Health (HL141855)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 22 June 2021
Revised: 8 December 2021
Accepted: 30 December 2021
First Online: 12 January 2022
Competing interests
: GGG is CEO, President and co-founder of FirstString Research Inc, which licensed αCT1 peptide. CLG is Senior Director of Research and Development at FirstString Research Inc. RGG is a non-remunerated member of the Scientific Advisory Board of FirstString Research, as well as a co-founder of the company. GGG, RGG, JJ, and CLG have ownership interests in FirstString Research Inc. The remaining authors have no disclosures to report.
